Nvidia is doubling down on artificial-intelligence-powered drug discovery and development, announcing expanded partnerships with Amgen and Recursion Pharmaceuticals.

In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine learning to make the process of ...

Executives from Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company, visit the Nasdaq MarketSite in Times Square on January 22 to ring the Nasdaq Opening Bell and celebrate the “Era of ...

Recursion shares jumped over 18% after launching Boltz-2, a breakthrough AI model with MIT that predicts molecular binding The open-source model significantly accelerates drug discovery, making ...